SCHEMBL141047

SCHEMBL141047

O=c1ccc(C(F)(F)F)cn1-c1ccc(Cl)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MIF P14174 1/20 0.46
ALDH1A1 P00352 3/20 0.42
HTT P42858 2/20 0.42
ALOX15 P16050 1/20 0.42
ATM Q13315 1/20 0.42
MAPT P10636 1/20 0.41
P2RX3 P56373 1/20 0.40
PTGS1 P23219 2/20 0.39
PTGS2 P35354 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.38
MGLL Q99685 1/20 0.37
HPGD P15428 2/20 0.37
KDM4E B2RXH2 1/20 0.37
CYP1A2 P05177 1/20 0.37
BLM P54132 1/20 0.37
HSD17B10 Q99714 1/20 0.37
CBL P22681 1/20 0.37
CBLB Q13191 1/20 0.37
MAPK1 P28482 1/20 0.37
GAA P10253 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12333052 0.89 GSK3A (0.42) ALDH1A1HPGDKDM4ECYP1A2BLM
SCHEMBL142716 0.84 NPC1 (0.46) ALDH1A1PTGS1PTGS2MGLLHPGD
SCHEMBL142926 0.82 KIF11 (0.47) ALDH1A1PTGS1PTGS2SMN1; SMN2MGLL
SCHEMBL13075264 0.82 ALDH1A1 (0.41) ALDH1A1HTTMAPTHPGDKDM4E
SCHEMBL29348797 0.82 KDM4E (0.42) ALDH1A1MGLLHPGDKDM4ECYP1A2
SCHEMBL10305669 0.82 ALDH1A1 (0.53) ALDH1A1MAPTPTGS1PTGS2MGLL
SCHEMBL10079418 0.82 KDM4E (0.37) ALDH1A1HTTMAPTHPGDKDM4E
SCHEMBL6116854 0.82 KIF11 (0.47) ALDH1A1HTTALOX15ATMPTGS1
SCHEMBL143208 0.81 ALDH1A1 (0.56) ALDH1A1MAPTSMN1; SMN2HPGDKDM4E
SCHEMBL12333478 0.79 ALDH1A1 (0.40) ALDH1A1SMN1; SMN2HPGDKDM4ECYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10010536-B2 Method of modulating stress-activated protein kinase system INTERMUNE, INC. (US) 2018-07-03 US disclosed
US-10010536-B2 Method of modulating stress-activated protein kinase system INTERMUNE, INC. (US) 2018-07-03 US disclosed
US-20170095462-A1 METHOD OF MODULATING STRESS-ACTIVATED PROTEIN KINASE SYSTEM INTERMUNE, INC. 2017-04-06 US disclosed
US-20170095462-A1 METHOD OF MODULATING STRESS-ACTIVATED PROTEIN KINASE SYSTEM INTERMUNE, INC. 2017-04-06 US disclosed
US-9527816-B2 Method of modulating stress-activated protein kinase system INTERMUNE, INC. (US) 2016-12-27 US disclosed
US-9527816-B2 Method of modulating stress-activated protein kinase system INTERMUNE, INC. (US) 2016-12-27 US disclosed
EP-2591784-B1 Pyridine-2-one-derivatives as modulators of stress-activated protein kinase system INTERMUNE INC (US) 2016-09-14 EP disclosed
EP-2474533-B1 PREPARATION OF 1-(SUBSTITUTED BENZYL)-5-TRIFLUOROMETHYL-2-(1H)PYRIDONE COMPOUNDS AND SALTS THEREOF AND THEIR APPLICATIONS UNIV CENTRAL SOUTH (CN) 2015-02-25 EP disclosed
EP-1928454-B1 PYRIDONE DERIVATIVES FOR MODULATING STRESS-ACTIVATED PROTEIN KINASE SYSTEM INTERMUNE INC (US) 2014-09-24 EP disclosed
US-20140228310-A1 METHOD OF MODULATING STRESS-ACTIVATED PROTEIN KINASE SYSTEM INTERMUNE, INC. (US) 2014-08-14 US disclosed
US-20100240704-A1 METHOD OF MODULATING STRESS-ACTIVATED PROTEIN KINASE SYSTEM INTERMUNE, INC. 2010-09-23 US disclosed
US-20100190731-A1 METHODS FOR TREATING ACUTE MYOCARDIAL INFARCTIONS AND ASSOCIATED DISORDERS INTERMUNE, INC. 2010-07-29 US disclosed
US-20100190731-A1 METHODS FOR TREATING ACUTE MYOCARDIAL INFARCTIONS AND ASSOCIATED DISORDERS INTERMUNE, INC. 2010-07-29 US disclosed
WO-2010085805-A1 METHODS FOR TREATING ACUTE MYOCARDIAL INFARCTIONS AND ASSOCIATED DISORDERS INTERMUNE, INC. (US) 2010-07-29 WO disclosed
US-7728013-B2 Method of modulating stress-activated protein kinase system INTERMUNE, INC. (US) 2010-06-01 US disclosed
US-7728013-B2 Method of modulating stress-activated protein kinase system INTERMUNE, INC. (US) 2010-06-01 US disclosed
US-20100029578-A1 Methods of Treating Atrial Fibrillation with P38 Inhibitor Compounds INTERMUNE, INC. 2010-02-04 US disclosed
WO-2007062167-A9 METHOD OF MODULATING STRESS-ACTIVATED PROTEIN KINASE SYSTEM INTERMUNE INC (US) 2007-07-26 WO disclosed
WO-2007062167-A2 METHOD OF MODULATING STRESS-ACTIVATED PROTEIN KINASE SYSTEM INTERMUNE, INC. (US) 2007-05-31 WO disclosed
WO-2007053685-A2 METHODS OF TREATING ATRIAL FIBRILLATION WITH P38 INHIBITOR COMPOUNDS INTERMUNE, INC. (US) 2007-05-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100190731-A1 METHODS FOR TREATING ACUTE MYOCARDIAL INFARCTIONS AND ASSOCIATED DISORDERS TNNI3, FABP3, TNNT2 MIF 9/4885ALDH1A1 94/4885HTT 4777/4885
US-20100240704-A1 METHOD OF MODULATING STRESS-ACTIVATED PROTEIN KINASE SYSTEM MAPKAPK2, MAP3K6, MAP4K1 MIF 587/4885ALDH1A1 3375/4885HTT 3688/4885
US-20100029578-A1 Methods of Treating Atrial Fibrillation with P38 Inhibitor Compounds ATF1, MAPKAPK3, MAPKAPK2 MIF 2735/4885ALDH1A1 900/4885HTT 4596/4885
US-10010536-B2 Method of modulating stress-activated protein kinase system MAPKAPK2, MAP3K6, MAP4K1 MIF 587/4885ALDH1A1 3375/4885HTT 3688/4885
US-20170095462-A1 METHOD OF MODULATING STRESS-ACTIVATED PROTEIN KINASE SYSTEM MAPKAPK2, MAP3K6, MAP4K1 MIF 587/4885ALDH1A1 3375/4885HTT 3688/4885
US-20140228310-A1 METHOD OF MODULATING STRESS-ACTIVATED PROTEIN KINASE SYSTEM MAPKAPK2, MAP3K6, MAP4K1 MIF 587/4885ALDH1A1 3375/4885HTT 3688/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.